Conduit Pharmaceuticals INC Form 4 insider transactions

CDT Equity Inc. reports significant insider transactions including stock purchases and warrant exercises by CEO Andrew Regan and related entities.

Mark Taylor, a director and 10% owner of CDT Equity Inc., significantly increased his indirect beneficial ownership through the cashless exercise of pre-funded warrants.

CDT Equity Inc. acquired shares of Sarborg Limited from Director Chele Chiavacci Farley and other stockholders, issuing common stock and pre-funded warrants.

CDT Equity Inc. issued common stock and pre-funded warrants to Corvus Capital Ltd. as consideration for the acquisition of Conduit Pharmaceuticals Limited.

CDT Equity Inc. granted its Chief Executive Officer and Director, Andrew Regan, 1,120,000 shares of common stock as compensation for his services.

CDT Equity Inc. CFO and Director James Bligh was granted 480,000 shares of restricted common stock, valued at approximately $329,424, which vested immediately under the company's incentive plan.

CDT Equity Inc. Director Simon Jeremy Fry received 35,000 restricted stock units and 15,000 stock options, both vesting immediately, as compensation for services.

CDT Equity Inc. Director Freda Lewis-Hall acquired 35,000 restricted stock units and 15,000 stock options, increasing her beneficial ownership.

CDT Equity Inc. Director Chele Chiavacci Farley reported the acquisition of 35,000 restricted stock units and 15,000 stock options.

Conduit Pharmaceuticals Inc. CEO Andrew Regan, through affiliated entities, acquired 154,799 shares of common stock as part of a $500,000 upfront payment for a joint development agreement, increasing his beneficial ownership.

Faith L. Charles resigned from the Board of Directors of Conduit Pharmaceuticals Inc. on April 16, 2025, and will no longer be subject to Section 16 reporting requirements.

Director Freda Lewis-Hall acquired 47,612 shares of Conduit Pharmaceuticals in lieu of a cash retainer, while also reporting indirect ownership of additional shares.

Director Simon Jeremy Fry acquired 29,354 shares of Conduit Pharmaceuticals Inc. common stock in lieu of a $26,125 cash retainer.

Chele Chiavacci Farley, a director of Conduit Pharmaceuticals, acquired 32,022 shares of common stock in lieu of $28,500 in cash retainers.

Director Faith L. Charles reports acquiring 46,629 shares and disposing of shares of Conduit Pharmaceuticals common stock on March 30, 2025.

Director Chele Chiavacci Farley acquired options to purchase 420,000 shares of Conduit Pharmaceuticals common stock at $0.071 per share.

Director Faith L. Charles reports the acquisition of stock options in Conduit Pharmaceuticals Inc.

Director Freda Lewis-Hall reports acquisition of stock options in Conduit Pharmaceuticals Inc.

Director Simon Jeremy Fry acquired options to purchase 420,000 shares of Conduit Pharmaceuticals common stock at a price of $0.071 per share on December 18, 2024.

Director Freda Lewis-Hall acquired 437,976 shares of Conduit Pharmaceuticals stock in lieu of a cash retainer, while also holding indirect ownership of additional shares through Intelmed LLC and her spouse.

Conduit Pharmaceuticals CEO, David Tapolczay, was granted 840,000 stock options on November 18, 2024, under the company's 2023 Stock Incentive Plan.

Director Chele Chiavacci Farley acquired 299,238 shares of Conduit Pharmaceuticals stock in lieu of $27,500 in cash retainers.

Conduit Pharmaceuticals' Interim CFO, James Bligh, was granted 1.89 million stock options on November 18, 2024, under the company's 2023 Stock Incentive Plan.

Director Faith L. Charles of Conduit Pharmaceuticals acquired 75,000 shares through a stock incentive plan and 266,594 shares in lieu of cash retainers.

Nirland Ltd, along with related entities, disposed of over 3.7 million shares of Conduit Pharmaceuticals (CDT) between October 3rd and October 7th, 2024.

Nirland Ltd, along with related entities, disposed of over 2.5 million shares of Conduit Pharmaceuticals Inc. between September 30 and October 2, 2024.

Andrew Regan, a director and 10% owner through Corvus Capital and Algo Holdings, reports a series of sales of Conduit Pharmaceuticals (CDT) common stock, significantly reducing Algo Holdings' stake.

Director Chele Chiavacci Farley reports acquiring and disposing of shares of Conduit Pharmaceuticals on June 11, 2024.

Interim CFO James Bligh reports acquiring 37,272 shares of Conduit Pharmaceuticals on June 11, 2024.

Adam Sragovicz, CFO of Conduit Pharmaceuticals, disposed of 74,545 Restricted Stock Units on May 15, 2024.